Member Info for Laura2022

Potter

What time please.?

15.21%

Open Short Positions in Wizz Air

Fund % Short Change Date Changed

Citadel Advisors Llc 0.61% 0.07% 19 Mar 2026

Point72 Europe (London) Llp 0.64% 0.06% 19 Mar 2026

Voleon Capital Management Lp 0.81% 0.09% 19 Mar 2026

Millennium International Management Lp 0.51% 0.02% 18 Mar 2026

Squarepoint Ops Llc 0.98% -0.12% 18 Mar 2026

Ahl Partners Llp 1.50% 0.10% 10 Mar 2026

Qube Research & Technologies Limited 0.52% 0.48% 10 Mar 2026

Two Sigma Investments, Lp 2.53% 0.10% 10 Mar 2026

D. E. Shaw & Co. Lp 3.12% 0.10% 9 Mar 2026

Pdt Partners, Llc 0.71% 0.11% 6 Mar 2026

Connor, Clark & Lunn Investment Management Ltd 0.51% 0.03% 5 Mar 2026

Jpmorgan Asset Management (Uk) Ltd 2.77% 0.40% 5 Mar 2026

Total

Has added another c 15mln to go to 56,000,000

(Prevously was 41mln)

16% shorts highest on FTSE

Full ask or NT for just £7000

Been watching amd wait9ng for 4 weeks

So oversold and 16% shorts need to close

Short

Moving up on mo volume really

Background buys ?

Market bounce

Under 0.16p

Not sure why gone SO far below placing.?

The Board of Spire Healthcare remains in discussions with other parties in relation to a potential sale of the Company.

Won't be long before a big move

Dr Huw Jones, Chief Executive Officer of TheraCryf, commented:

"We continue to deliver a potentially class leading asset on target for clinic readiness in the fourth quarter of this year, exactly in line with the plan outlined at the start of this project. The substance use disorder market is already worth over US$42 billion growing to over US$71 billion¹ over the next seven years.

These conditions cause more deaths than road accidents and substance abusers lose over 20 years of life compared to non-abusers2. The licensing market to large pharma for such treatments is considerable, generating substantial returns to originating companies at the right stage of development. With a class leading profile, we anticipate generating significant commercial interest in TheraCryf's Ox-1 asset."

TheraCryf plc (AIM: TCF), the biotech company developing new medicines for addiction and other neuropsychiatric disorders, today announces completion of preclinical dose range finding studies for its lead orexin-1 (Ox-1) receptor antagonist programme being developed for addiction, a market worth US$42 billion¹ and an area attracting significant clinical and commercial interest from large pharmaceutical companies.

As anyone with a brain knew from the January update which Stewart etc questioned:)

The Board of Spire Healthcare remains in discussions with other parties in relation to a potential sale of the Company. There can be no certainty that any offer will be made for the Company nor as to the terms of any offer, if made.

The Company is participating across seven procurement frameworks, generating 20+ bid opportunities since April 2025.

· RC Fornax is in advanced discussions on three major agreements, two with defence primes for land and maritime programmes.

Herman

Think there will be contacts soon

Its all explained towards the bottom of the original RNS

As a result of entering into the Sharing Agreement, the aggregate amount received by the Company under the Lanstead Subscription and the Sharing Agreement may be more or less than £6 million, as further explained below. Notwithstanding the Subscription Price of 6.0 pence, shareholders should note that the share price of the Company needs to be on average over the 20 months of the Sharing Agreement at or above the Benchmark Price of 8.0 pence per share for the Company to receive at least, or more than, the gross Subscription of £6 million.

 

Theyve put the "dark days " of 2021-23 behind had cut overheads down from $17llnn to c.$12mln

As of Dec 2025 they stated the situation below, but now nearly in April they should still have 6-9mths head room , but maybe market wants more certainty?

The cash burn in Q4 FY25 was $1.3m, representing a 59% reduction compared to Q4 FY24.

As of 31 December 2025, the unaudited cash position was $4.0m and short-term trade receivables balance was $3.4m, giving a cash plus short-term receivables balance of $7.4m.